Gi Cell (지아이셀)

GI Cell was founded by Dr. Myoung Ho Jang, an intestinal immunologist, in Oct 2018. 82 employees (as of Mar 2021) are working in our company and around 40% (15/41) of R&D members are Ph.D. GI Cell has innovative platform technology for screening and optimizing ancillary proteins for target immune cells. Several cell therapy pipelines for treatment of cancer, inflammatory disorders are in the pre-clinical development stages. GI Cell also develop multi-valent sub-unit vaccines for COVID-19 based on experience in ancillary protein engineering and profound understanding in immunology. 1) Immune Cell pure Expander : Platform technology that enables screening and optimizing ancillary proteins to maximize expansion capacity, purity, and functional activity of target immune cells during cultivation. With this optimized ancillary protein, we epigenetically improve NK cell, CD8 T cell, Treg cell to have high potency and targeting efficiency without cancerous feeder cell (in case of NK cell) and genetic engineering. For more information, please visit our websites or contact by e-mail (contact@gi-cell.com).